Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Shares Climb 6 Percent One Day After Firm Reported 11-Percent Revenue Growth

NEW YORK, Jan. 28 (GenomeWeb News) - Shares in PerkinElmer were up 5.57 percent, or $1.20, at $22.75 in late-afternoon trading today, one day after the company reported substantial gains in revenue during the fourth quarter.

 

The Massachusetts-based company said yesterday that total receipts jumped 11 percent in the fourth quarter of 2004. The increase was spurred by revenue in its Life and Analytical Sciences division.

 

Total company revenue for the three months ended Dec. 31 shot up to $478 million from $431.8 million in the year-ago period. The Life and Analytical Sciences division saw revenue grow to $311 million in the fourth quarter of 2004 from $290 million in the same period last year -- a rise of 6.8 percent.

 

The company attributed the division's growth during the quarter to "double digit" revenue growth in its genetic-screening, -service and environmental businesses.

 

PerkinElmer's R&D expenses for the fourth quarter of 2004 were up $4.7 million to $23.6 million.

 

Net income grew 27 percent, as PerkinElmer reported $37.9 million for the fourth quarter of 2004, compared to $27.9 million year-over-year.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.